Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.45 |
| ▸ | S100A9 | P06702 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5011758 | 0.93 | PNMT (0.44) | PNMTTAAR1IDO1CA1CA2 | |
| SCHEMBL8372485 | 0.83 | IDO1 (0.52) | PNMTTAAR1IDO1S100A9CYP3A4 | |
| SCHEMBL31374431 | 0.83 | IDO1 (0.52) | PNMTTAAR1IDO1S100A9CYP3A4 | |
| SCHEMBL20758770 | 0.82 | CA1 (0.44) | PNMTTAAR1CA1CA2CA9 | |
| SCHEMBL17375023 | 0.82 | CA2 (0.44) | PNMTTAAR1IDO1CA1CA2 | |
| SCHEMBL271305 | 0.81 | IDO1 (0.50) | PNMTTAAR1IDO1SLC6A2SLC6A4 | |
| SCHEMBL23036770 | 0.80 | CA2 (0.41) | CA1CA2CA9CA5ASLC6A2 | |
| SCHEMBL2377549 | 0.79 | IDO1 (0.48) | PNMTTAAR1IDO1S100A9CYP3A4 | |
| SCHEMBL9421739 | 0.79 | GSTO1 (0.60) | PNMTTAAR1IDO1S100A9CYP3A4 | |
| SCHEMBL11702627 | 0.79 | IDO1 (0.48) | PNMTTAAR1IDO1S100A9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. (CA) | 2025-05-20 | — | — | US | disclosed |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2023-12-07 | — | — | US | disclosed |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | ZYMEWORKS BC INC. | 2023-04-04 | — | — | US | disclosed |
| US-11518739-B2 | Sulfonamide carboxamide compounds | INFLAZOME LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| EP-3087091-B1 | VAR2CSA-DRUG CONJUGATES | ZYMEWORKS INC (CA) | 2021-10-20 | — | — | EP | disclosed |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200216389-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LIMITED (IE) | 2020-07-09 | — | — | US | disclosed |
| US-10675355-B2 | VAR2CSA-drug conjugates | VAR2 PHARMACEUTICALS APS (DK) | 2020-06-09 | — | — | US | disclosed |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | ZYMEWORKS BC INC. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-22 | — | — | US | disclosed |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | WYETH LLC | 2009-12-10 | — | — | US | disclosed |
| US-7582772-B2 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| EP-1778629-A1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | Wyeth (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006023611-A1 | PROCESS FOR THE SYNTHESIS C-2, C-3 SUBSTITUTED N-ALKYLATED INDOLES USEFUL AS CPLA2 INHIBITORS | WYETH (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060041005-A1 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | WYETH (US) | 2006-02-23 | — | — | US | disclosed |
| WO-1994018165-A1 | SULFONAMIDE COMPOUNDS AS OPIOID K-RECEPTOR AGONISTS | PFIZER INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| US-4428956-A | GLYCOLATE OXIDASE INHIBITORS | MERCK & CO., INC. (US) | 1984-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200216389-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, PYCARD | PNMT 4760/4885TAAR1 2555/4885IDO1 1701/4885 |
| US-11617777-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | PNMT 1637/4885TAAR1 4759/4885IDO1 3356/4885 |
| US-20060041005-A1 | Process for the synthesis C-2, C-3 substituted N-alkylated indoles useful as CPLA2 inhibitors | PLA2G4A, PLA2R1, PLA2G12A | PNMT 657/4885TAAR1 1091/4885IDO1 67/4885 |
| US-10675355-B2 | VAR2CSA-drug conjugates | VARS1, GUSB, VAV1 | PNMT 1820/4885TAAR1 3833/4885IDO1 4552/4885 |
| US-10851098-B2 | Azole amides and amines as alpha v integrin inhibitors | ITGAV, ITGB1, ITGA1 | PNMT 1740/4885TAAR1 564/4885IDO1 848/4885 |
| US-20090306428-A1 | Process for the Synthesis of C-2, C-3 Substituted N-Alkylated Indoles Useful as cPLA2 Inhibitors | PLA2G4A, PLA2G12A, PLA2R1 | PNMT 716/4885TAAR1 1013/4885IDO1 58/4885 |
| US-20190269785-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | PNMT 1637/4885TAAR1 4759/4885IDO1 3356/4885 |
| US-12303544-B2 | Cytotoxic and anti-mitotic compounds, and methods of using the same | CCNB1, PLK1, BOD1L1 | PNMT 1637/4885TAAR1 4759/4885IDO1 3356/4885 |
| US-20230390354-A1 | CYTOTOXIC AND ANTI-MITOTIC COMPOUNDS, AND METHODS OF USING THE SAME | CCNB1, PLK1, BOD1L1 | PNMT 1637/4885TAAR1 4759/4885IDO1 3356/4885 |
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | PNMT 2230/4885TAAR1 1568/4885IDO1 3058/4885 |
| US-20190256513-A1 | AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB1, ITGA1 | PNMT 1740/4885TAAR1 564/4885IDO1 848/4885 |
| US-11518739-B2 | Sulfonamide carboxamide compounds | NLRP3, PYCARD, NOD1 | PNMT 4707/4885TAAR1 2561/4885IDO1 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.